Cecil DL - Search Results

1

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer.

Cecil DL, Curtis B, Gad E, Gormley M, Timms AE, Corulli L, Bos R, Damle RN, Sepulveda MA, Disis ML. Cecil DL, et al. Sci Rep. 2022 Aug 10;12(1):13618. doi: 10.1038/s41598-022-17950-1. Sci Rep. 2022. PMID: 35948756 Free PMC article.

2

Breast cancer vaccines for treatment and prevention.

Disis ML, Cecil DL. Disis ML, et al. Among authors: cecil dl. Breast Cancer Res Treat. 2022 Feb;191(3):481-489. doi: 10.1007/s10549-021-06459-2. Epub 2021 Nov 30. Breast Cancer Res Treat. 2022. PMID: 34846625 Review.

3

T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.

Cecil DL, Park KH, Gad E, Childs JS, Higgins DM, Plymate SR, Disis ML. Cecil DL, et al. Breast Cancer Res Treat. 2013 Jun;139(3):657-65. doi: 10.1007/s10549-013-2577-z. Epub 2013 Jun 8. Breast Cancer Res Treat. 2013. PMID: 23749321

4

Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.

Corulli LR, Cecil DL, Gad E, Koehnlein M, Coveler AL, Childs JS, Lubet RA, Disis ML. Corulli LR, et al. Among authors: cecil dl. Front Immunol. 2021 Aug 30;12:729809. doi: 10.3389/fimmu.2021.729809. eCollection 2021. Front Immunol. 2021. PMID: 34526999 Free PMC article.

5

Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.

Cecil D, Park KH, Curtis B, Corulli L, Disis MN. Cecil D, et al. J Immunother Cancer. 2021 Mar;9(3):e002355. doi: 10.1136/jitc-2021-002355. J Immunother Cancer. 2021. PMID: 33762321 Free PMC article.

6

A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.

Disis ML, Gad E, Herendeen DR, Lai VP, Park KH, Cecil DL, O'Meara MM, Treuting PM, Lubet RA. Disis ML, et al. Among authors: cecil dl. Cancer Prev Res (Phila). 2013 Dec;6(12):1273-82. doi: 10.1158/1940-6207.CAPR-13-0182. Epub 2013 Oct 23. Cancer Prev Res (Phila). 2013. PMID: 24154719 Free PMC article.

7

Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Cecil DL, Holt GE, Park KH, Gad E, Rastetter L, Childs J, Higgins D, Disis ML. Cecil DL, et al. Cancer Res. 2014 May 15;74(10):2710-8. doi: 10.1158/0008-5472.CAN-13-3286. Epub 2014 Apr 28. Cancer Res. 2014. PMID: 24778415 Free PMC article.

8

Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.

Watt WC, Cecil DL, Disis ML. Watt WC, et al. Among authors: cecil dl. Semin Immunopathol. 2017 Apr;39(3):245-253. doi: 10.1007/s00281-016-0596-7. Epub 2016 Dec 14. Semin Immunopathol. 2017. PMID: 27975138 Review.

9

Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.

Cecil DL, Slota M, O'Meara MM, Curtis BC, Gad E, Dang Y, Herendeen D, Rastetter L, Disis ML. Cecil DL, et al. Clin Cancer Res. 2017 Jul 1;23(13):3396-3404. doi: 10.1158/1078-0432.CCR-16-1678. Epub 2016 Dec 30. Clin Cancer Res. 2017. PMID: 28039264 Free PMC article.

10

Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers.

Disis ML, Corulli LR, Gad EA, Koehnlein MR, Cecil DL, Senter PD, Gardai SJ, Okeley NM. Disis ML, et al. Among authors: cecil dl. Mol Cancer Ther. 2020 May;19(5):1102-1109. doi: 10.1158/1535-7163.MCT-19-0500. Epub 2020 Mar 12. Mol Cancer Ther. 2020. PMID: 32165557

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page